132 completed, 31 unknown, 30 recruiting, 29 terminated. 257 Phase 3, 35 Phase 2.
Follow Blood Platelet Disorders: new trials by email Literature Review of Blood Platelet Disorders trials Research Report on Blood Platelet Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia Sutacimig - Thrombasthenia | Phase 3 | Recruiting | Hemab ApS | 76 | 2026-10-27 | 2026-11-13 |
| rhTPO for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Procedures. rhTPO, Placebo - Thrombocytopenia Associated With Chronic Liver Disease | Phase 3 | Recruiting | MIBIO PTE. LTD. | 150 | 2026-10-20 | 2026-11-06 |
| Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study Hetrombopag, Placebo - Thrombocytopenia, Hepatic Interventional Procedure | Phase 3 | Not yet recruiting | Zhongda Hospital | 108 | 2026-10-15 | 2026-11-09 |
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-11-13 |
| A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP) Romiplostim, Predniso(lo)ne - Primary Immune Thrombocytopenia | Phase 3 | Recruiting | Amgen | 126 | 2026-08-21 | 2026-09-17 |
| Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon | Phase 2 / Phase 3 | Recruiting | Yi Ji | 76 | 2026-06-16 | 2026-06-18 |
| Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia Sirolimus, Placebo - Systemic Lupus Erythematosus, Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | Chinese SLE Treatment And Research Group | 164 | 2026-06-07 | 2026-06-18 |
| ATRA for Management of Primary ITP all-trans retinoic acid (ATRA), Placebo - Immune Thrombocytopenia | Phase 3 | Not yet recruiting | Peking University People's Hospital | 192 | 2026-05-30 | 2026-05-19 |
| Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients QL0911, Placebo - Thrombocytopenia, Immune | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 60 | 2026-04-20 | 2026-03-06 |
| High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia High-Dose Dexamethasone Combined with Orelabrutinib, High-Dose Dexamethasone Combined with Placebo - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | Shandong University | 86 | 2026-04-08 | 2026-04-30 |
| Comparison of Etamsylate Versus Placebo to Prevent Bleeding in HSCT etamsylate, Placebo - Hematopoietic Stem Cell Transplantation, Thrombocytopenia | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 404 | 2025-12-16 | 2026-03-02 |
| Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune Thrombocytopenia Avatrombopag+All trans retinoic acid, Avatrombopag - ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 248 | 2025-12-01 | 2025-12-12 |
| An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia Human immunoglobulin (pH4) for intravenous injection - Primary Immune Thrombocytopenia (ITP) | Phase 3 | Recruiting | Grand Shuyang Life Sciences (Chengdu) Co., Ltd. | 36 | 2025-11-24 | 2026-04-08 |
| Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment rilzabrutinib - Immune Thrombocytopenia | Phase 3 | Recruiting | Sanofi | 60 | 2025-10-24 | 2026-11-12 |
| A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP) Efgartigimod IV, Placebo IV - Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia | Phase 2 / Phase 3 | Recruiting | argenx | 24 | 2025-10-20 | 2026-11-16 |
| Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD) VGA039 - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Vega Therapeutics, Inc | 60 | 2025-10-15 | 2026-09-14 |
| Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan rilzabrutinib - Immune Thrombocytopenia | Phase 3 | Active not recruiting | Sanofi | 3 | 2025-10-15 | 2026-11-10 |
| A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD) VONVENDI, ADVATE - Von Willebrand Disease (VWD) | Phase 3 | Recruiting | Takeda | 20 | 2025-10-13 | 2026-01-08 |
| The Holistic Study Avatrombopag, Rituximab (Arm B) - Thrombocytopenia Purpura | Phase 3 | Not yet recruiting | Ostfold Hospital Trust | 220 | 2025-09-15 | 2025-09-09 |
| A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia Mezagitamab - Immune Thrombocytopenic Purpura (ITP) | Phase 3 | Recruiting | Takeda | 150 | 2025-08-14 | 2026-10-30 |
Showing 20 of 257. Sign in to see all of them.
Purpura, Thrombocytopenic, Idiopathic (120) · Thrombocytopenia (70) · Thrombocythemia, Essential (31) · Primary Myelofibrosis (20) · von Willebrand Diseases (19) · Polycythemia Vera (18) · Myeloproliferative Disorders (15) · Leukemia, Myeloid, Acute (14) · Blast Crisis (13) · Hematologic Diseases (13) · Leukemia, Myeloid, Accelerated Phase (13) · Leukemia, Myeloid, Chronic-Phase (13) · Lymphoma, Follicular (13) · Lymphoma, Non-Hodgkin (13) · Thrombotic Microangiopathies (13)
Hemic and Lymphatic Diseases (256) · Hematologic Diseases (244) · Cytopenia (205) · Blood Coagulation Disorders (183) · Hemorrhagic Disorders (168) · Pathological Conditions, Signs and Symptoms (161) · Pathologic Processes (158) · Signs and Symptoms (144) · Thrombotic Microangiopathies (143) · Immune System Diseases (140) · Thrombocytopenia (135) · Skin Manifestations (132) · Hemorrhage (128) · Purpura (122)
eltrombopag (21) · Dexamethasone (18) · Rituximab (16) · romiplostim (15) · Immunoglobulins, Intravenous (14) · avatrombopag (12) · Factor VIII (10) · Thrombopoietin (10) · Prednisone (8) · anagrelide (7) · Prednisolone (6) · ravulizumab (6) · Hydroxyurea (5) · Standard of Care (5) · von Willebrand Factor (5)
Shandong University (18) · Amgen (10) · Novartis Pharmaceuticals (8) · Assistance Publique - Hôpitaux de Paris (7) · argenx (7) · Baxalta now part of Shire (6) · GlaxoSmithKline (6) · Takeda (6) · Alexion Pharmaceuticals, Inc. (5) · Octapharma (5) · Peking University People's Hospital (5) · Sanofi (5) · Sobi, Inc. (5) · The First Affiliated Hospital of Soochow University (5) · AOP Orphan Pharmaceuticals AG (4)
United States (105) · China (73) · France (63) · Italy (63) · United Kingdom (59) · Spain (56) · Germany (55) · Poland (49) · Japan (42) · Canada (41) · Russia (39) · Australia (34) · Czechia (33) · Austria (32) · Hungary (32)
Ming Hou, Dr (5) · Ming Hou, Dr. (4) · James George, MD (3) · Charlotte Bradbury (2) · Cindy Leissinger, MD (2)
PMID 19005182, PMID 19671919, PMID 33783815, PMID 33995988, PMID 34219224, PMID 40277027, PMID 12944568, PMID 17077333, PMID 18242413, PMID 19846889, PMID 21533818, PMID 22117897, PMID 22494019, PMID 25566808, PMID 29778606, PMID 32047671, PMID 33275766, PMID 11824975, PMID 12966125, PMID 15459300, PMID 15803929, PMID 17397698, PMID 18510702, PMID 19109560, PMID 19635187, PMID 19731307, PMID 20130241, PMID 20164484, PMID 20841509, PMID 20863431, PMID 21266777, PMID 21325604, PMID 21503695, PMID 21713321, PMID 22409309, PMID 22480131, PMID 22496156, PMID 22538854, PMID 22871490, PMID 22913681, PMID 23169778, PMID 23278371, PMID 23293082, PMID 23315161, PMID 2334081, PMID 23462431, PMID 23492914, PMID 23753021, PMID 23896965, PMID 24254965
2023 (12), 2016 (5), 2019 (5), 2009 (4), 2014 (3), 2017 (3), U01HL072268 (3), 2025 (2), 2004 (1), 2008 (1), 2015 (1), 2018 (1), P01CA108671 (1), P30CA068485 (1), R01CA127655 (1)